Pemetrexed Injection Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 100 mg/4 mL vial, 500 mg/20 mL vial

Reference Brands: -

Category: Oncology Cancer Care

Pemetrexed 25 mg/mL ready-to-dilute injection in 100 mg/4 mL and 500 mg/20 mL vials, an antifolate for lung cancer and mesothelioma. Supplied to oncology hospitals, cancer centre pharmacies, importers and tender buyers.

Product Description:

Pemetrexed is an antifolate cytotoxic agent. It blocks several folate-dependent enzymes, mainly thymidylate synthase, so tumour cells cannot make the building blocks of DNA. This page lists a ready-to-dilute solution at 25 mg/mL, in 100 mg/4 mL and 500 mg/20 mL vials. The older presentation is a lyophilised powder that must be reconstituted first. The solution removes that step in the aseptic unit, saving time and handling, though it is still diluted before infusion. Check each label for compatible diluents.

Pemetrexed is used in non-squamous non-small cell lung cancer, with platinum first-line, alongside immunotherapy in many protocols, and as maintenance. With cisplatin it is a standard first-line regimen for malignant pleural mesothelioma. It is infused over ten minutes every 21 days. Daily oral folic acid and vitamin B12 injections, started before the first dose, reduce toxicity, and a corticosteroid around each dose limits rash. Kidney function is checked each cycle, and NSAIDs need care. Marrow suppression is dose-limiting.

Sourcing notes. Pemetrexed is a prescription-only cytotoxic medicine for hospital oncology. Generic registration is national in CTD or ACTD format, from a sterile site with GMP approval for cytotoxics. Storage varies: powder vials are kept at room temperature, while several ready-to-dilute solutions need 2 to 8 °C, so take the condition from the specific label and plan transport to match. Ask for a batch CoA with sterility and endotoxins, the GMP certificate, a CoPP and in-use stability after dilution. State concentration, vial size and quantity.